News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
737,571 Results
Type
Article (42255)
Company Profile (267)
Press Release (695036)
Multimedia
Podcasts (131)
Webinars (21)
Section
Business (206081)
Career Advice (2052)
Deals (35754)
Drug Delivery (154)
Drug Development (82064)
Employer Resources (174)
FDA (16693)
Job Trends (15069)
News (349269)
Policy (33427)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (3)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (6)
Academia (2627)
Accelerated approval (53)
ADA (44)
Adcomms (27)
Allergies (180)
Alliances (49891)
ALS (222)
Alzheimer's disease (1825)
Antibody-drug conjugate (ADC) (493)
Approvals (17104)
Artificial intelligence (699)
ASCO (327)
Autoimmune disease (324)
Automation (58)
Bankruptcy (364)
Best Places to Work (11671)
BIOSECURE Act (21)
Biosimilars (231)
Biotechnology (171)
Bladder cancer (200)
Brain cancer (74)
Breast cancer (784)
Cancer (6132)
Cardiovascular disease (498)
Career advice (1747)
Career pathing (44)
CAR-T (347)
CDC (60)
Celiac Disease (3)
Cell therapy (941)
Cervical cancer (52)
Clinical research (71577)
Collaboration (2141)
Company closure (5)
Compensation (1454)
Complete response letters (86)
COVID-19 (2771)
CRISPR (111)
C-suite (1177)
Cystic fibrosis (155)
Data (8383)
Decentralized trials (3)
Denatured (30)
Depression (166)
Dermatology (93)
Diabetes (668)
Diagnostics (7016)
Digital health (59)
Diversity (13)
Diversity, equity & inclusion (46)
Drug discovery (340)
Drug pricing (223)
Drug shortages (36)
Duchenne muscular dystrophy (296)
Earnings (92609)
Editorial (69)
Employer branding (21)
Employer resources (153)
Events (120959)
Executive appointments (1106)
FDA (20559)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (19)
Frontotemporal dementia (35)
Funding (1785)
Gene editing (239)
Generative AI (59)
Gene therapy (745)
GLP-1 (1214)
Government (5050)
Grass and pollen (7)
Guidances (414)
Healthcare (19291)
Hematology (192)
HIV (84)
Huntington's disease (58)
IgA nephropathy (110)
Immunology and inflammation (297)
Immuno-oncology (99)
Indications (202)
Infectious disease (3126)
Inflammatory bowel disease (219)
Inflation Reduction Act (15)
Influenza (137)
Intellectual property (305)
Interviews (322)
IPO (16720)
IRA (51)
Job creations (3694)
Job search strategy (1448)
JPM (60)
Kidney cancer (20)
Labor market (107)
Layoffs (579)
Leadership (42)
Legal (8045)
Liver cancer (103)
Longevity (33)
Lung cancer (817)
Lymphoma (452)
Machine learning (61)
Management (59)
Manufacturing (1115)
MASH (208)
Medical device (14041)
Medtech (14185)
Mergers & acquisitions (20311)
Metabolic disorders (1727)
mRNA (218)
Multiple sclerosis (194)
NASH (19)
Neurodegenerative disease (446)
Neuropsychiatric disorders (106)
Neuroscience (3411)
Neurotech (1)
NextGen: Class of 2026 (6558)
Non-profit (4581)
Now hiring (80)
Obesity (832)
Opinion (295)
Ovarian cancer (233)
Pain (262)
Pancreatic cancer (329)
Parkinson's disease (381)
Partnered (33)
Patents (617)
Patient recruitment (707)
Peanut (66)
People (60043)
Pharmaceutical (60)
Pharmacy benefit managers (34)
Phase 1 (22283)
Phase 2 (31494)
Phase 3 (23517)
Pipeline (9360)
Policy (342)
Postmarket research (2594)
Preclinical (9484)
Press Release (65)
Prostate cancer (326)
Psychedelics (55)
Radiopharmaceuticals (339)
Rare diseases (1129)
Real estate (6018)
Recruiting (70)
Regulatory (25942)
Reports (56)
Research institute (2436)
Resumes & cover letters (356)
Rett syndrome (41)
RNA editing (23)
RSV (88)
Schizophrenia (181)
Series A (299)
Series B (220)
Service/supplier (12)
Sickle cell disease (119)
Special edition (25)
Spinal muscular atrophy (171)
Sponsored (48)
Startups (3671)
State (2)
Stomach cancer (18)
Supply chain (133)
Tariffs (96)
The Weekly (98)
Vaccines (1134)
Venture capital (117)
Weight loss (563)
Women's health (131)
Worklife (20)
Date
Today (165)
Last 7 days (720)
Last 30 days (3030)
Last 365 days (30502)
2026 (14636)
2025 (30334)
2024 (35378)
2023 (40210)
2022 (51351)
2021 (55934)
2020 (54380)
2019 (46972)
2018 (35350)
2017 (32304)
2016 (31745)
2015 (37800)
2014 (31568)
2013 (26558)
2012 (28763)
2011 (29440)
2010 (27552)
Location
Africa (761)
Alabama (93)
Alaska (7)
Arizona (355)
Arkansas (14)
Asia (40101)
Australia (6604)
California (13717)
Canada (3909)
China (1438)
Colorado (583)
Connecticut (600)
Delaware (423)
Europe (87241)
Florida (2051)
Georgia (439)
Hawaii (3)
Idaho (64)
Illinois (1106)
India (94)
Indiana (622)
Iowa (23)
Japan (564)
Kansas (132)
Kentucky (50)
Louisiana (56)
Maine (76)
Maryland (1636)
Massachusetts (9805)
Michigan (370)
Minnesota (740)
Mississippi (6)
Missouri (154)
Montana (33)
Nebraska (29)
Nevada (145)
New Hampshire (85)
New Jersey (3594)
New Mexico (30)
New York (3587)
North Carolina (1732)
North Dakota (9)
Northern California (6907)
Ohio (410)
Oklahoma (23)
Oregon (41)
Pennsylvania (2742)
Puerto Rico (29)
Rhode Island (51)
South America (1127)
South Carolina (86)
South Dakota (2)
Southern California (5431)
Tennessee (219)
Texas (2185)
United States (48348)
Utah (405)
Vermont (1)
Virginia (331)
Washington D.C. (81)
Washington State (1097)
West Virginia (4)
Wisconsin (130)
Wyoming (2)
737,571 Results for "novo nordisk canada inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
GLP-1
Generic of Novo’s GLP-1 arrives in Canada, a ‘test case for the world’
Analysts will be watching as a generic version of semaglutide—marketed by Novo Nordisk as Wegovy for weight loss—launches in Canada as a test case for future price erosion in the U.S.
April 29, 2026
·
3 min read
·
Annalee Armstrong
Press Releases
Novo Nordisk Canada and Rexall Pharmacy partner to offer convenience, support, and home delivery for Canadians taking Ozempic® and Wegovy®
May 13, 2026
·
4 min read
Earnings
Novo’s Wegovy pill reaches 1M patients, shattering expectations with $355M in sales
Analysts and investors alike had been eagerly awaiting sales figures for Novo Nordisk’s Wegovy pill. The answer blew past expectations by 86%.
May 6, 2026
·
4 min read
·
Annalee Armstrong
Obesity
ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold
Novo Nordisk and Eli Lilly presented data extolling the benefits of their relative weight loss therapies in obesity-linked indications, while analysts at BMO Capital Markets were “encouraged” by the strategy communicated by Novo management.
June 8, 2026
·
5 min read
·
Heather McKenzie
Sickle cell disease
Novo’s late-stage sickle cell win piles pressure on competitors
Novo Nordisk’s etavopivat elicited a 27% drop in vaso-occlusive crises and 48.7% hemoglobin response after 24 weeks, creating “separation amongst PK class candidates,” Truist analysts said on Monday. Novo plans to seek FDA approval in the back half of 2026.
April 20, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Novo Nordisk Introduces Extra Savings for Canadians Who Choose Ozempic®
May 26, 2026
·
2 min read
Obesity
Lilly and Novo face off at ADA 2026 as others seek to compete in obesity
The American Diabetes Association’s annual congress will feature a superstar lineup, including weight loss giants Eli Lilly and Novo Nordisk. But several scrappy biotechs will also present obesity candidates with the potential to match—if not outperform—their deep-pocketed competitors.
June 5, 2026
·
8 min read
·
Tristan Manalac
Obesity
Boehringer, Zealand’s obesity drug ‘more akin’ to Novo’s Wegovy in Phase 3
Topline Phase 3 results of survodutide—licensed to Boehringer Ingelheim from Zealand Pharma—are more comparable to Novo Nordisk’s Wegovy than to Eli Lilly’s Zepbound, William Blair analysts said on Tuesday.
April 28, 2026
·
2 min read
·
Heather McKenzie
Layoffs
Layoffs at Novo’s Ex-Catalent Site Despite Signs of Turnaround, Continued Investment
As Novo Nordisk cuts 400 jobs at the troubled site, Scholar Rock has seen enough progress that it included the facility in a resubmission for FDA approval.
April 1, 2026
·
2 min read
·
Nick Paul Taylor
Press Releases
Novo Nordisk A/S - share repurchase programme - June 8, 2026
June 8, 2026
·
2 min read
1 of 73,758
Next
